Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2018

Open Access 01-12-2018 | Commentary

Does glucagon have a positive inotropic effect in the human heart?

Author: Jesus Hernández-Cascales

Published in: Cardiovascular Diabetology | Issue 1/2018

Login to get access

Abstract

Glucagon is considered to exert cardiostimulant effects, most notably the enhancement of heart rate and contractility, due to the stimulation of glucagon receptors associated with Gs protein stimulation which causes adenylyl cyclase activation and the consequent increase in 3′,5′-cyclic adenosine monophosphate production in the myocardium. These effects have been extensively demonstrated in experimental studies in different animal species. However, efforts to extrapolate the experimental data to patients with low cardiac output states, such as acute heart failure or cardiogenic shock, have been disappointing. The experimental and clinical data on the cardiac effects of glucagon are described here.
Literature
1.
go back to reference Cerriello A, Genovese S, Mannucci E, Gronda E. Glucagon snd heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016;15:123.CrossRef Cerriello A, Genovese S, Mannucci E, Gronda E. Glucagon snd heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016;15:123.CrossRef
2.
go back to reference Petersen KM, BØgevig S, Holst JJ, Knop FK, Christensen MB. Hemodynamic effects of glucagon: a literature review. J Clin Endocrinol Metab. 2018;103:1804–12.CrossRef Petersen KM, BØgevig S, Holst JJ, Knop FK, Christensen MB. Hemodynamic effects of glucagon: a literature review. J Clin Endocrinol Metab. 2018;103:1804–12.CrossRef
4.
go back to reference Vinogradova TM, Lakatta EG. Regulation of basal and reserve cardiac pacemaker function by interactions of cAMP-mediated PKA-dependent Ca2+ cycling with surface membrane channels. J Mol Cell Pharmacol. 2009;47:456–74. Vinogradova TM, Lakatta EG. Regulation of basal and reserve cardiac pacemaker function by interactions of cAMP-mediated PKA-dependent Ca2+ cycling with surface membrane channels. J Mol Cell Pharmacol. 2009;47:456–74.
5.
go back to reference Winter J, Brack KE, Ng A. Cardiac contractility modulation in the treatment of heart failure: initial results and unanswered questions. Eur J Hart Fail. 2011;13:700–10.CrossRef Winter J, Brack KE, Ng A. Cardiac contractility modulation in the treatment of heart failure: initial results and unanswered questions. Eur J Hart Fail. 2011;13:700–10.CrossRef
6.
go back to reference Farah A, Tuttle R. Studies on pharmacology of glucagon. J Pharmacol Exp Ther. 1960;129:49–56.PubMed Farah A, Tuttle R. Studies on pharmacology of glucagon. J Pharmacol Exp Ther. 1960;129:49–56.PubMed
7.
go back to reference White CM. A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol. 1999;39:442–7.PubMed White CM. A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol. 1999;39:442–7.PubMed
8.
go back to reference Rodgers RL, MacLeod KM, McNeill JH. Responses of rat an guinea pig hearts to glucagon. Circ Res. 1981;49:216–25.CrossRef Rodgers RL, MacLeod KM, McNeill JH. Responses of rat an guinea pig hearts to glucagon. Circ Res. 1981;49:216–25.CrossRef
9.
10.
go back to reference Furukawa Y, Saegusa K, Ogiwara Y, Chiba S. Different effectiveness of glucagon on the pacemaker activity and contractility in intact dog hearts and in isolated perfused right atria. Jpn Heart J. 1986;27:215–22.CrossRef Furukawa Y, Saegusa K, Ogiwara Y, Chiba S. Different effectiveness of glucagon on the pacemaker activity and contractility in intact dog hearts and in isolated perfused right atria. Jpn Heart J. 1986;27:215–22.CrossRef
11.
go back to reference Gonzalez-Muñoz C, Nieto-Cerón S, Cabezas-Herrera J, Hernández-Cascales J. Glucagon increases contractility in ventricle but not in atrium of the rat heart. Eur J Pharmacol. 2008;587:243–7.CrossRef Gonzalez-Muñoz C, Nieto-Cerón S, Cabezas-Herrera J, Hernández-Cascales J. Glucagon increases contractility in ventricle but not in atrium of the rat heart. Eur J Pharmacol. 2008;587:243–7.CrossRef
12.
go back to reference Antonaccio MJ, Cavaliere T. A comparison of the effects of some inotropic and chronotropic agents on isolated atria from normotensive (NTR) and spontaneously hypertensive (SHR) rats. Arch Int Pharmacodyn Ther. 1974;209:273–82.PubMed Antonaccio MJ, Cavaliere T. A comparison of the effects of some inotropic and chronotropic agents on isolated atria from normotensive (NTR) and spontaneously hypertensive (SHR) rats. Arch Int Pharmacodyn Ther. 1974;209:273–82.PubMed
13.
go back to reference Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon. N Engl J Med. 1968;279:12–7.CrossRef Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon. N Engl J Med. 1968;279:12–7.CrossRef
14.
go back to reference Lvoff R, Wilcken DEL. Glucagon in heart failure and in cardiogenic shock. Circulation. 1972;45:534–42.CrossRef Lvoff R, Wilcken DEL. Glucagon in heart failure and in cardiogenic shock. Circulation. 1972;45:534–42.CrossRef
15.
go back to reference Vander CR, Reynolds EW, Mich AA. Clinical evaluation of glucagon by continuous infusion in the treatment of low cardiac output states. Am Heart J. 1970;79:481–7.CrossRef Vander CR, Reynolds EW, Mich AA. Clinical evaluation of glucagon by continuous infusion in the treatment of low cardiac output states. Am Heart J. 1970;79:481–7.CrossRef
16.
go back to reference Hamer J, Gibson D, Coltar J. Effect of glucagon on left ventricular performance in aortic stenosis Br Heart J. 1973;35:312–9.PubMed Hamer J, Gibson D, Coltar J. Effect of glucagon on left ventricular performance in aortic stenosis Br Heart J. 1973;35:312–9.PubMed
17.
go back to reference Murtagh JG, Binnion PF, Lal S, Hutchison KJ. Haemodynamic effects of glucagon. Br Heart J. 1970;32:307–15.CrossRef Murtagh JG, Binnion PF, Lal S, Hutchison KJ. Haemodynamic effects of glucagon. Br Heart J. 1970;32:307–15.CrossRef
18.
go back to reference Sélley E, Kun S, Szijárto IA, Kertesz M, Wittmann I, Molnar GA. Vasodilator effect of glucagon: receptorial crosstalk among glucagon, GLP-1 and receptor for glucagons and GLP-1. Horm Metab Res. 2016;48:476–83.CrossRef Sélley E, Kun S, Szijárto IA, Kertesz M, Wittmann I, Molnar GA. Vasodilator effect of glucagon: receptorial crosstalk among glucagon, GLP-1 and receptor for glucagons and GLP-1. Horm Metab Res. 2016;48:476–83.CrossRef
19.
go back to reference Rosano GMC, Vitale C. Metabolic modulation of cardiac metabolism in heart failure. Card Fail Rev. 2018;4:99–103.CrossRef Rosano GMC, Vitale C. Metabolic modulation of cardiac metabolism in heart failure. Card Fail Rev. 2018;4:99–103.CrossRef
20.
go back to reference Prasad K. Electrophysiologic effects of glucagon on human cardiac muscle. Clin Pharmacol Ther. 1975;18:22–30.CrossRef Prasad K. Electrophysiologic effects of glucagon on human cardiac muscle. Clin Pharmacol Ther. 1975;18:22–30.CrossRef
21.
go back to reference Baiio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, Cappola TP, Margulies KB, Drucker DJ. GLP-1 receptor expression within the human heart. Endocrinology. 2018;159:1570–84.CrossRef Baiio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, Cappola TP, Margulies KB, Drucker DJ. GLP-1 receptor expression within the human heart. Endocrinology. 2018;159:1570–84.CrossRef
22.
go back to reference Jess R, Schneider KW, Deeg P. The effect of intravenous infucion of glucagon on the contractility of the left ventricular myocardium in man. Basic Res Cardiol. 1975;70:217–26.CrossRef Jess R, Schneider KW, Deeg P. The effect of intravenous infucion of glucagon on the contractility of the left ventricular myocardium in man. Basic Res Cardiol. 1975;70:217–26.CrossRef
23.
go back to reference Thuesen L, Christiansen JS, Sorensen KE, Orskov H, Henningsen P. Low-dose intravenous glucagon has no effect on myocardial contractility in normal man. An echocardiographic study. Scand J Clin Lab Invest. 1988;48:71–5.CrossRef Thuesen L, Christiansen JS, Sorensen KE, Orskov H, Henningsen P. Low-dose intravenous glucagon has no effect on myocardial contractility in normal man. An echocardiographic study. Scand J Clin Lab Invest. 1988;48:71–5.CrossRef
24.
go back to reference Nord HJ, Fontanes AL, Williams JF. Treatment of congestive heart failure with glucagon. Ann Int Med. 1970;72:649–53.CrossRef Nord HJ, Fontanes AL, Williams JF. Treatment of congestive heart failure with glucagon. Ann Int Med. 1970;72:649–53.CrossRef
25.
go back to reference Kones RJ, Phillips JH. Glucagon in congestive heart failure. Chest. 1971;59:392–7.CrossRef Kones RJ, Phillips JH. Glucagon in congestive heart failure. Chest. 1971;59:392–7.CrossRef
26.
go back to reference Forfang K, Falch D, Frey HMM, Fremstad D. Chronic congestive heart failure treated with long-term infusion of glucagon. Acta Med Scand. 1973;194:563–6.CrossRef Forfang K, Falch D, Frey HMM, Fremstad D. Chronic congestive heart failure treated with long-term infusion of glucagon. Acta Med Scand. 1973;194:563–6.CrossRef
27.
go back to reference Writing committee members; ACC/AHA task force members. ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. J Cardial Fail. 2016;22:659–69.CrossRef Writing committee members; ACC/AHA task force members. ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. J Cardial Fail. 2016;22:659–69.CrossRef
28.
go back to reference DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and β-blocker toxicity. Toxicol Rev. 2004;23:223–38.CrossRef DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and β-blocker toxicity. Toxicol Rev. 2004;23:223–38.CrossRef
29.
go back to reference Shepherd G. Treatment of poisoning caused by β-adrenergic and calcium-channel blockers. Am J Health-Syst Pharm. 2006;63:1828–34.CrossRef Shepherd G. Treatment of poisoning caused by β-adrenergic and calcium-channel blockers. Am J Health-Syst Pharm. 2006;63:1828–34.CrossRef
30.
go back to reference Shimizu H, Egawa M, Yoshimatsu H, Bray GA. Glucagon injected in the lateral hypothalamus stimulates sympathetic activity and suppresses monoamine metabolism. Brain Res. 1993;630:95–100.CrossRef Shimizu H, Egawa M, Yoshimatsu H, Bray GA. Glucagon injected in the lateral hypothalamus stimulates sympathetic activity and suppresses monoamine metabolism. Brain Res. 1993;630:95–100.CrossRef
31.
go back to reference Chernow B, Reed L, Geelhoed GW, Anderson M, Teich S, Meyerhoff J, Beardsley D, Lake CR, Holaday JW. Glucagon: endocrine effects and calcium involvement in cardiovascular actions in dogs. Circ Shock. 1986;19:393–407.PubMed Chernow B, Reed L, Geelhoed GW, Anderson M, Teich S, Meyerhoff J, Beardsley D, Lake CR, Holaday JW. Glucagon: endocrine effects and calcium involvement in cardiovascular actions in dogs. Circ Shock. 1986;19:393–407.PubMed
Metadata
Title
Does glucagon have a positive inotropic effect in the human heart?
Author
Jesus Hernández-Cascales
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2018
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-018-0791-z

Other articles of this Issue 1/2018

Cardiovascular Diabetology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.